16:05 EST Vanda Pharmaceuticals (VNDA) sees FY26 revenue $230M-$260M, consensus $271.27M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- VNDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vanda Pharmaceuticals Advances Ponesimod Into Phase 3 Psoriasis Study: What Investors Should Know
- Maintaining Buy Rating on Vanda: Limited Impact from Tasimelteon Setback, Ongoing FDA Engagement, and Bysanti Catalyst Support $22 Target
- H.C. Wainwright says rejection of Vanda’s tasimelteon ‘only minor setback’
- Vanda Faces FDA Setback on HETLIOZ Jet Lag Application